Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
Updated: Sep 24
23/09/2026
Roche’s sefaxersen significantly reduced proteinuria in IgA nephropathy (Ref)
Roche reported positive prespecified interim results from Ph3 IMAgINATION study of sefaxersen (ASO targeting complement factor B) in adults with primary IgA nephropathy (IgAN).
The trial met its primary endpoint, demonstrating statistically significant and clinically meaningful improvements in proteinuria reduction vs placebo at week 37 measured by 24-hour UPCR.
The study will continue to assess kidney function over two years measured by eGFR at week 105.
Immunovant’s IMVT-1402 failed to meet the primary endpoint in CLE (Ref)
Immunovant reported topline results from period 1 of its Ph2/ NCT06980805 proof-of-concept study of IMVT-1402 (imeroprubart; anti-FcRn) in adults with cutaneous lupus erythematosus (CLE).
The study did not achieve statistical significance on the primary endpoint of CLASI-A % change from baseline at Week 12.
IMVT-1402 showed a favorable safety and tolerability profile. However, Immunovant will stop its development in CLE based on competitive landscape and the clinical results.


